{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T08:21:40Z","timestamp":1787473300482,"version":"build-2736575974"},"reference-count":89,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This review updates knowledge on the Kell (International Society of Blood Transfusion [ISBT] 006) and Kx (ISBT 019) blood group systems since the last review published in\n                    <jats:italic>Immunohematology<\/jats:italic>\n                    in 2015. It highlights new insights into the relationship between Kell glycoprotein and red blood cell (RBC) membrane stability, including recent discoveries of new antigens and alleles, and reporting of the first diagnosis of McLeod syndrome in an infant. The Kell and Kx blood group systems welcome an increasing number of antigens and\/or alleles to their systems. Kell has a total of 38 antigens as of January 2025; a further 25 novel alleles encode K\n                    <jats:sub>mod<\/jats:sub>\n                    phenotypes, and an additional 71 nucleotide changes are associated with the K\n                    <jats:sub>0<\/jats:sub>\n                    (null) phenotype. XK follows a similar theme with an ever-increasing number of new alleles, all encoding the Kx\u2013 (null) phenotype. The review emphasizes the role of molecular diagnostics in resolving serologic ambiguities in the blood bank or assisting the diagnosis of neurodegenerative syndromes. The monitoring and management of anti-K in pregnancy is evolving. Emerging technologies such as single-cell sequencing and multi-omics analysis workflows, gene editing, and cellular therapeutics may unlock the inner workings of Kell and Kx protein mechanics and elucidate the function of Kell protein biology, structural immunogenicity, and explain why alloanti-K is capable of suppressing erythroid growth.\n                  <\/jats:p>","DOI":"10.2478\/immunohematology-2025-014","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:57:19Z","timestamp":1761890239000},"page":"90-99","source":"Crossref","is-referenced-by-count":0,"title":["Kell and Kx blood group systems: an update"],"prefix":"10.2478","volume":"41","author":[{"given":"Candice L.","family":"Davison","sequence":"first","affiliation":[{"name":"Pathology and Clinical Governance, Australian Red Cross Lifeblood, Brisbane , Queensland , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Denomme","sequence":"additional","affiliation":[{"name":"Grifols Diagnostics Solutions, Emeryville , CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026082308010209658_j_immunohematology-2025-014_ref_001","unstructured":"ISBT Blood Group Allele Database: 006 KEL and 019 KX Alleles. International Society of Blood Transfusion; 2021-2023. Available from https:\/\/www.isbtweb.org\/isbt-working-parties\/rcibgt.html. Accessed 31 January 2025."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_002","doi-asserted-by":"crossref","unstructured":"Lee S, Russo D, Redman CM. The Kell blood group system: Kell and XK membrane proteins. Semin Hematol 2000;37:113\u201321.","DOI":"10.1016\/S0037-1963(00)90036-2"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_003","doi-asserted-by":"crossref","unstructured":"Lee S, Zambas ED, Marsh WL, Redman CM. Molecular cloning and primary structure of Kell blood group protein. Proc Natl Acad Sci U S A 1991;88:6353\u20137.","DOI":"10.1073\/pnas.88.14.6353"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_004","doi-asserted-by":"crossref","unstructured":"Lee S, Lin M, Mele A, et al. Proteolytic processing of big endothelin-3 by the Kell blood group protein. Blood 1999;94:1440\u201350.","DOI":"10.1182\/blood.V94.4.1440.416k01_1440_1450"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_005","doi-asserted-by":"crossref","unstructured":"Lee S, Russo DCW, Reiner AP, et al. Molecular defects underlying the Kell null phenotype. J Biol Chem 2001;276:27281\u20139.","DOI":"10.1074\/jbc.M103433200"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_006","doi-asserted-by":"crossref","unstructured":"Ho M, Chelly J, Carter N, Danek A, Crocker P, Monaco AP. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994;77:869\u201380.","DOI":"10.1016\/0092-8674(94)90136-8"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_007","doi-asserted-by":"crossref","unstructured":"Allen FH Jr, Krabbe SM, Corcoran PA. A new phenotype (McLeod) in the Kell blood-group system. Vox Sang 1961; 6:555\u201360.","DOI":"10.1111\/j.1423-0410.1961.tb03203.x"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_008","doi-asserted-by":"crossref","unstructured":"Denomme GA. Kell and Kx blood group systems. Immunohematology 2015;31:14\u20139.","DOI":"10.21307\/immunohematology-2019-065"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_009","doi-asserted-by":"crossref","unstructured":"Lee S. Molecular basis of Kell blood group phenotypes. Vox Sang 1997;73:1\u201311.","DOI":"10.1159\/000461892"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_010","doi-asserted-by":"crossref","unstructured":"Stanfield GM, Horvitz HR. The ced-8 gene controls the timing of programmed cell deaths in C elegans. Mol Cell 2000;5: 423\u201333.","DOI":"10.1016\/S1097-2765(00)80437-2"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_011","doi-asserted-by":"crossref","unstructured":"Lee S, Russo D, Redman C. Functional and structural aspects of the Kell blood group system. Transfus Med Rev 2000;14: 93\u2013103.","DOI":"10.1016\/S0887-7963(00)80001-2"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_012","doi-asserted-by":"crossref","unstructured":"Camara-Clayette V, Rahuel C, Lopez C, et al. Transcriptional regulation of the KEL gene and Kell protein expression in erythroid and non-erythroid cells. Biochem J 2001;356: 171\u201380.","DOI":"10.1042\/bj3560171"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_013","doi-asserted-by":"crossref","unstructured":"Clap\u00e9ron A, Rose C, Gane P, Collec E, Bertrand O, Ouimet T. The Kell protein of the common K2 phenotype is a catalytically active metalloprotease, whereas the rare Kell K1 antigen is inactive: identification of novel substrates for the Kell protein. J Biol Chem 2005;280:21272\u201383.","DOI":"10.1074\/jbc.M500100200"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_014","doi-asserted-by":"crossref","unstructured":"Lee S, Debnath AK, Redman CM. Active amino acids of the Kell blood group protein and model of the ectodomain based on the structure of neutral endopeptidase 24.11. Blood 2003;102:3028\u201334.","DOI":"10.1182\/blood-2003-05-1564"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_015","doi-asserted-by":"crossref","unstructured":"Azouzi S, Collec E, Mohandas N, An X, Colin Y, Le Van Kim C. The human Kell blood group binds the erythroid 4.1R protein: new insights into the 4.1R-dependent red cell membrane complex. Br J Haemotol 2015;17:862\u201371.","DOI":"10.1111\/bjh.13778"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_016","unstructured":"New Zealand Blood Service. Policy for the provision of K negative red cells to females with child bearing potential (National Policy Document 111P01702). Available from https:\/\/www.nzblood.co.nz\/assets\/Transfusion-Medicine\/PDFs\/111P017.pdf. Accessed 7 February 2025."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_017","doi-asserted-by":"crossref","unstructured":"Goldman M, Lane D, Webert K, Fallis R. The prevalence of anti-K in Canadian prenatal patients. Transfusion 2015; 55:1486\u201391.","DOI":"10.1111\/trf.13151"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_018","doi-asserted-by":"crossref","unstructured":"Luken JS, Folman CC, Lukens MV, et al. Reduction of anti-K-mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: a nation-wide policy change evaluation study in the Netherlands. Transfusion 2021;61: 713\u201321.","DOI":"10.1111\/trf.16276"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_019","doi-asserted-by":"crossref","unstructured":"Luken JS, Folman CC, Meekers JH, Lukens MV, van der Schoot CE, de Haas M. Major reduction in occurrence of anti-c and anti-E in pregnancy after more than 10 years of preventive matched transfusion with most benefit for c-matching. Br J Haematol 2024;205:1599\u2013604.","DOI":"10.1111\/bjh.19740"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_020","doi-asserted-by":"crossref","unstructured":"Regan F, Veale K, Robinson F, et al. Guideline for the investigation and management of red cell antibodies in pregnancy: a British Society for Haematology guideline. Transfus Med 2025;35:3\u201323.","DOI":"10.1111\/tme.13098"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_021","unstructured":"Australian and New Zealand Society of Blood Transfusion. Guidelines for transfusion and immunohaematology laboratory practice. Available from https:\/\/anzsbt.org.au\/guidelines\/guidelines-for-transfusion-and-immunohaematology-laboratory-practice\/. Accessed 17 September 2025."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_022","doi-asserted-by":"crossref","unstructured":"Gleadall NS, Veldhuisen B, Gollub J, et al. Development and validation of a universal blood donor genotyping platform: a multinational prospective study. Blood Adv 2020;4:3495\u2013506.","DOI":"10.1182\/bloodadvances.2020001894"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_023","doi-asserted-by":"crossref","unstructured":"Fasano RM, Chou ST. Red blood cell antigen genotyping for sickle cell disease, thalassemia, and other transfusion complications. Transfus Med Rev 2016;30:197\u2013201.","DOI":"10.1016\/j.tmrv.2016.05.011"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_024","doi-asserted-by":"crossref","unstructured":"Flegel WA, Gottschall JL, Denomme GA. Implementing mass-scale red cell genotyping at a blood center. Transfusion 2015;55:2610\u20135; quiz 2609.","DOI":"10.1111\/trf.13168"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_025","doi-asserted-by":"crossref","unstructured":"Jacko G, Powley T, Daly J. Frequency of red blood cell phenotypes from genotyped Australian blood donors. Transfus Med 2024;34:219\u201322.","DOI":"10.1111\/tme.13044"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_026","doi-asserted-by":"crossref","unstructured":"Akinbolaji TJ. When and why is red blood cell genotyping applicable in transfusion medicine: a systematic review of the literature. Immunohematology 2024;40:58\u201364.","DOI":"10.2478\/immunohematology-2024-009"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_027","unstructured":"Grey D, Poole J, Martin P, et al. P23: haemolytic disease of the newborn caused by a new Kell antigen. Transfus Med 2003;13(Suppl 1):30."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_028","unstructured":"Martin-Blanc S, Laget L, Babinet J, et al. Characterization of a novel high prevalence antigen in the KEL blood group system. Vox Sang 2022;117(Suppl 1):6\u2013271."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_029","unstructured":"Hyland C, Buhariwala K, Lopez G, et al. Intertwining roles for genomics and international data sharing defines a novel low prevalence Kell antigen in a blood donor. Transfus Med 2022;32(Suppl 3):11."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_030","doi-asserted-by":"crossref","unstructured":"Lopez GH, Buhariwala KN, Condon JA, et al. KHOZ (KEL41): a novel low-prevalence antigen in the Kell blood group system antithetical to KHIZ (KEL40). Transfusion. 2025;65:E25\u20137.","DOI":"10.1111\/trf.18254"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_031","unstructured":"Karamatic-Crew V, Poole J, Watson T, Bullock T, Burton N, Daniels G. KASH (KEL34): a novel high incidence antigen in the Kell blood group system. Vox Sang 2010;99(Suppl 1):357."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_032","unstructured":"Karamatic-Crew V, Poole J, Bullock T, Malde R, Burton N, Daniels G. Abstracts - PO11: KELP (KEL35): a new high incidence antigen in the Kell blood group system defined by two homozygous missense mutations in KEL. Transfus Med 2010;20(Suppl 1):30."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_033","unstructured":"Karamatic-Crew V, Poole J, Bullock T, Regan P, Burton N, Daniels G. KETI, a novel high incidence antigen in the Kell blood group system: a serological and molecular study. Vox Sang 2011;101(Suppl 1):19."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_034","doi-asserted-by":"crossref","unstructured":"Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook: Kell blood group system. 3rd ed. Academic Press, San Diego, CA, 2012.","DOI":"10.1016\/B978-0-12-415849-8.00008-9"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_035","doi-asserted-by":"crossref","unstructured":"Allen FH Jr, Lewis SJ, Fudenberg H. Studies of anti-Kpb, a new antibody in the Kell blood group system. Vox Sang 1958;3: 1\u201313.","DOI":"10.1159\/000478363"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_036","doi-asserted-by":"crossref","unstructured":"Giollo M, Minervini G, Scalzotto M, Leonardi E, Ferrari C, Tosatto SC. BOOGIE: predicting blood groups from high throughput sequencing data. PLoS One. 2015;10:e0124579.","DOI":"10.1371\/journal.pone.0124579"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_037","doi-asserted-by":"crossref","unstructured":"M\u00f6ller M, J\u00f6ud M, Storry JR, Olsson ML. Erythrogene: a database for in-depth analysis of the extensive variation in 36 blood group systems in the 1000 Genomes Project. Blood Adv 2016;1:240\u20139.","DOI":"10.1182\/bloodadvances.2016001867"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_038","doi-asserted-by":"crossref","unstructured":"Schoeman EM, Lopez GH, McGowan EC, et al. Evaluation of targeted exome sequencing for 28 protein-based blood group systems, including the homologous gene systems, for blood group genotyping. Transfusion 2017;57:1078\u201388.","DOI":"10.1111\/trf.14054"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_039","doi-asserted-by":"crossref","unstructured":"Lane WJ, Vege S, Mah HH, et al. Automated typing of red blood cell and platelet antigens from whole exome sequences. Transfusion 2019;59:3253\u201363.","DOI":"10.1111\/trf.15473"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_040","unstructured":"Lane WJ, Westhoff CM, Gleadall NS, et al. Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. Lancet Haematol 2018;5:e241\u201351."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_041","doi-asserted-by":"crossref","unstructured":"Matosinho CGR, Silva CGR, Martins ML, Silva-Malta MCF. Next generation sequencing of red blood cell antigens in transfusion medicine: systematic review and meta-analysis. Transfus Med Rev 2024;38:150776.","DOI":"10.1016\/j.tmrv.2023.150776"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_042","doi-asserted-by":"crossref","unstructured":"Redman CM, Lee S. A historical perspective on the discovery of the Kell blood group carriers. Transfusion 2013;53(11 Suppl 2):2831\u20133.","DOI":"10.1111\/trf.12405"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_043","doi-asserted-by":"crossref","unstructured":"Scharberg EA, Wieckhusen C, Luz B, et al. Fatal hemolytic disease of the newborn caused by an antibody to KEAL, a new low-prevalence Kell blood group antigen. Transfusion 2017;57:217\u20138.","DOI":"10.1111\/trf.13852"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_044","doi-asserted-by":"crossref","unstructured":"Lomas-Francis C, Vege S, Velliquette RW, et al. Expansion of the Kell blood group system: two new high-prevalence antigens and two novel K0 (Kell null ) phenotypes. Transfusion 2013;53(11 Suppl 2):2887\u201391.","DOI":"10.1111\/trf.12377"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_045","doi-asserted-by":"crossref","unstructured":"Deleers M, Guizani M, Jani J, Hulot M, El Kenz H. A case of severe foetal anaemia due to anti-Kell that could not be detected by the weekly assessment of middle cerebral artery peak systolic velocity. Transfus Apher Sci 2018;57:111\u20133.","DOI":"10.1016\/j.transci.2018.01.005"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_046","doi-asserted-by":"crossref","unstructured":"Savoia HF, Parakh A, Kane SC. How I manage pregnant patients who are alloimmunized to RBC antigens. Blood 2025;145:2275\u201382.","DOI":"10.1182\/blood.2023022894"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_047","doi-asserted-by":"crossref","unstructured":"Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009;114:4279\u201382.","DOI":"10.1182\/blood-2009-06-227793"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_048","doi-asserted-by":"crossref","unstructured":"Pelc-K\u0142opotowska M, P\u0142oski R, Szcza\u0142uba K, et al. A novel KEL c.1414-1G>T allele in a polish patient with anti-Ku antibody. Transfusion 2022;62:E43\u20134.","DOI":"10.1111\/trf.17040"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_049","doi-asserted-by":"crossref","unstructured":"Denomme GA, Anani WQ. Mass-scale red cell genotyping of blood donors: from data visualization to historical antigen labeling and donor recruitment. Transfusion 2019;59:2768\u2013","DOI":"10.1111\/trf.15419"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_050","doi-asserted-by":"crossref","unstructured":"Moncharmont P, Barday G, Benamara H. Low incidence of post-transfusion Kell (KEL1) alloimmunisation in patients under 50 years old. Transfus Med 2020;30:70\u20132.","DOI":"10.1111\/tme.12652"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_051","unstructured":"Philips C, Scholes T. Making every unit count: the Kell conundrum. Transfus Med 2019;29(Suppl 2):35."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_052","doi-asserted-by":"crossref","unstructured":"Vaughan JI, Warwick R, Letsky E, Nicolini U, Rodeck CH, Fisk NM. Erythropoietic suppression in fetal anemia because of Kell alloimmunization. Am J Obstet Gynecol 1994;171:247\u201352.","DOI":"10.1016\/0002-9378(94)90477-4"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_053","doi-asserted-by":"crossref","unstructured":"Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 1998;338:798\u2013803.","DOI":"10.1056\/NEJM199803193381204"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_054","doi-asserted-by":"crossref","unstructured":"Daniels G, Hadley A, Green CA. Causes of fetal anemia in hemolytic disease due to anti-K. Transfusion 2003;43:115\u20136.","DOI":"10.1046\/j.1537-2995.2003.00327.x"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_055","doi-asserted-by":"crossref","unstructured":"Jacobs JW, Sugrue RP, Federspiel JJ, et al. The utility of a critical antibody titer in anti-K alloimmunized pregnancies: a systematic review and meta-analysis of diagnostic test accuracy. Transfus Med Rev 2025;39:150895.","DOI":"10.1016\/j.tmrv.2025.150895"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_056","doi-asserted-by":"crossref","unstructured":"Alshehri AA, Jackson DE. Non-invasive prenatal fetal blood group genotype and its application in the management of hemolytic disease of fetus and newborn: systematic review and meta-analysis. Transfus Med Rev 2021;35:85\u201394.","DOI":"10.1016\/j.tmrv.2021.02.001"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_057","doi-asserted-by":"crossref","unstructured":"Slootweg YM, Lindenburg IT, Koelewijn JM, Van Kamp IL, Oepkes D, De Haas M. Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol 2018;219:393. e391\u20133.e398.","DOI":"10.1016\/j.ajog.2018.07.020"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_058","doi-asserted-by":"crossref","unstructured":"Ohto H, Denomme GA, Ito S, Ishida A, Nollet KE, Yasuda H. Three non-classical mechanisms for anemic disease of the fetus and newborn, based on maternal anti-Kell, anti-Ge3, anti-M, and anti-Jr(a) cases. Transfus Apher Sci 2020;59:102949.","DOI":"10.1016\/j.transci.2020.102949"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_059","unstructured":"Lee E, De Silva M. Unlike anti-C, anti-K in pregnancy is more likely to have been induced by previous transfusion; this can be prevented. Transfusion 2004;44(Suppl):104A."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_060","unstructured":"Royal Australian and New Zealand College of Obstetricians and Gynaecologists. The management of women with red cell antibodies during pregnancy (green-top guideline no. 65). Available from https:\/\/ranzcog.edu.au\/wp-content\/uploads\/RCOG-Red-Cell-Antibodies-During-Pregnancy.pdf. Accessed 7 February 2025."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_061","doi-asserted-by":"crossref","unstructured":"O\u2019Brien H, Hyland C, Schoeman E, Flower R, Daly J, Gardener G. Non-invasive prenatal testing (NIPT) for fetal Kell, Duffy and Rh blood group antigen prediction in alloimmunised pregnant women: power of droplet digital PCR. Br J Haematol 2020;189:e90\u20134.","DOI":"10.1111\/bjh.16500"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_062","unstructured":"Australian Red Cross Lifeblood. Fetal blood group testing: NIPA for clinically significant fetal blood group antigens. Available from https:\/\/www.lifeblood.com.au\/health-professionals\/red-cell-reference\/fetal-blood-group-testing. Accessed 1 March 2025."},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_063","doi-asserted-by":"crossref","unstructured":"Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion 2007;47:2126\u201333.","DOI":"10.1111\/j.1537-2995.2007.01437.x"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_064","doi-asserted-by":"crossref","unstructured":"Zaki-Dizaji M, Shafiee A, Kohandel Gargari O, Fathi H, Heidary Z. Maternal and fetal factors affecting cell-free fetal DNA (cffDNA) fraction: a systematic review. J Reprod Infertil 2023;24:219\u201331.","DOI":"10.18502\/jri.v24i4.14149"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_065","doi-asserted-by":"crossref","unstructured":"Elsayed H, Ng M, Rutherford M, Gupta R. Bilateral cystic encephalomalacia follow ing multiple intrauterine transfusions for anti-Kell isoimmunisation. BMJ Case Rep 2015;2015:bcr2013202750.","DOI":"10.1136\/bcr-2013-202750"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_066","doi-asserted-by":"crossref","unstructured":"Phung TV, Houfflin-Debarge V, Ramdane N, et al. Maternal red blood cell alloimmunization requiring intrauterine transfusion: a comparative study on management and outcome depending on the type of antibody. Transfusion 2018;58:1199\u2013205.","DOI":"10.1111\/trf.14542"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_067","doi-asserted-by":"crossref","unstructured":"Lydaki E, Nikoloudi I, Kaminopetros P, et al. Serial blood donations for intrauterine transfusions of severe hemolytic disease of the newborn with the use of recombinant erythropoietin in a pregnant woman alloimmunized with anti-Ku. Transfusion 2005;45:1791\u20135.","DOI":"10.1111\/j.1537-2995.2005.00604.x"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_068","doi-asserted-by":"crossref","unstructured":"Virk M, Papakonstantino K, Cai W, Oh D, Andrews J. Blood donation during pregnancy due to anti-Ku hemolytic disease of the fetus and newborn. Lab Med 2019;50:421\u20135.","DOI":"10.1093\/labmed\/lmz020"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_069","doi-asserted-by":"crossref","unstructured":"Mattaloni SM, Arnoni C, C\u00e9spedes R, et al. Clinical significance of an alloantibody against the Kell blood group glycoprotein. Transfus Med Hemother 2017;44:53\u20137.","DOI":"10.1159\/000448381"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_070","doi-asserted-by":"crossref","unstructured":"Vlachodimitropoulou E, Lo TK, Bambao C, et al. Intravenous immunoglobulin in the management of severe early onset red blood cell alloimmunisation. Br J Haematol 2023;200:100\u20136.","DOI":"10.1111\/bjh.18449"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_071","doi-asserted-by":"crossref","unstructured":"Laurencin C, Sebbag L, Jousserand G, et al. Novel XK mutation in a McLeod patient diagnosed after heart transplant. Clin Neurol Neurosurg 2018;168:64\u20136.","DOI":"10.1016\/j.clineuro.2018.02.039"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_072","doi-asserted-by":"crossref","unstructured":"Wu PC, McGowan EC, Lee YQ, Ghosh S, Hansson J, Olsson ML. Epigenetic dissection of human blood group genes reveals regulatory elements and detailed characteristics of and four other loci. Transfusion 2024;64:1083\u201396.","DOI":"10.1111\/trf.17840"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_073","doi-asserted-by":"crossref","unstructured":"F\u00fcrst D, Tsamadou C, Neuchel C, Schrezenmeier H, Mytilineos J, Weinstock C. Next-generation sequencing technologies in blood group typing. Transfus Med Hemother 2020;47:4\u201313.","DOI":"10.1159\/000504765"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_074","doi-asserted-by":"crossref","unstructured":"Mayr G, Bublitz M, Steiert TA, et al. A structure-based in silico analysis of the Kell blood group system. Front Immunol 2024;15:1452637.","DOI":"10.3389\/fimmu.2024.1452637"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_075","doi-asserted-by":"crossref","unstructured":"De Franceschi L, Scardoni G, Tomelleri C, et al. Computational identification of phospho-tyrosine sub-networks related to acanthocyte generation in neuroacanthocytosis. PLoS One 2012;7:e31015.","DOI":"10.1371\/journal.pone.0031015"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_076","doi-asserted-by":"crossref","unstructured":"Fikrig SM, Phillipp JC, Smithwick EM, Oyen R, Marsh WL. Chronic granulomatous disease and McLeod syndrome in a black child. Pediatrics 1980;66:403\u20134.","DOI":"10.1542\/peds.66.3.403"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_077","doi-asserted-by":"crossref","unstructured":"Braun AA, Jung HH. Systematic review of phenotypes in McLeod syndrome and case report of a progressive supranuclear palsy in a female carrier. Orphanet J Rare Dis 2024;19:312.","DOI":"10.1186\/s13023-024-03309-4"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_078","doi-asserted-by":"crossref","unstructured":"Walker RH, Barreto M, Bateman JR, et al. The protean presentations of XK disease (McLeod syndrome): a case series with new observations and updates on previously reported families. Front Neurosci 2024;18:1408105.","DOI":"10.3389\/fnins.2024.1408105"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_079","doi-asserted-by":"crossref","unstructured":"Yu H, Li L, Li X, Liu H. Clinical features and novel pathogenic variants of Chinese patients with McLeod syndrome and choreaacanthocytosis. Mol Genet Genomic Med 2024;12: e70015.","DOI":"10.1002\/mgg3.70015"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_080","doi-asserted-by":"crossref","unstructured":"Blackstone WZ, Malaguit SE, Shwaish NS, Frandsen EL. Contiguous Xp21 deletion involving Duchenne muscular dystrophy and McLeod neuroacanthocytosis syndrome results in rapidly progressive and fatal cardiomyopathy. Cardiol Young 2025;35:358\u201360.","DOI":"10.1017\/S1047951124036370"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_081","doi-asserted-by":"crossref","unstructured":"Cloos AS, Ghodsi M, Stommen A, et al. Red blood cell lipid distribution in the pathophysiology and laboratory evaluation of chorea-acanthocytosis and McLeod syndrome patients. Front Physiol 2025;16:1543812.","DOI":"10.3389\/fphys.2025.1543812"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_082","doi-asserted-by":"crossref","unstructured":"Fujimori K, Shimizu S, Ishikawa T, et al. Hematopoietic cell transplantation in a patient with X-linked chronic granulomatous disease with McLeod phenotype. Pediatr Transplant 2025;29:e70086.","DOI":"10.1111\/petr.70086"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_083","doi-asserted-by":"crossref","unstructured":"Roulis E, Hyland C, Flower R, Gassner C, Jung HH, Frey BM. Molecular basis and clinical overview of McLeod syndrome compared with other neuroacanthocy tosis syndromes: a review. JAMA Neurol 2018;75:1554\u201362.","DOI":"10.1001\/jamaneurol.2018.2166"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_084","doi-asserted-by":"crossref","unstructured":"Dambietz CA, Doescher A, Heming M, et al. Case report: clinical, genetic and immunological characterization of a novel XK variant in a patient with McLeod syndrome. Front Genet 2024;15:1421952.","DOI":"10.3389\/fgene.2024.1421952"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_085","doi-asserted-by":"crossref","unstructured":"Tian PC, Wang Y, Chen Z, Shi DD, Wang HL, Luo Q. The first case report of McLeod syndrome in an infant with a novel mutation (c.89C>A, p. Ser30X) in XK. Clin Neurol Neurosurg 2019;184:105421.","DOI":"10.1016\/j.clineuro.2019.105421"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_086","doi-asserted-by":"crossref","unstructured":"Peikert K, Hermann A, Danek A. XK-associated McLeod syndrome: nonhematological manifestations and relation to VPS13A disease. Transfus Med Hemother 2022;49:4\u201312.","DOI":"10.1159\/000521417"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_087","doi-asserted-by":"crossref","unstructured":"Trakarnsanga K, Griffiths R, Wilson M, et al. An immortalized adult human erythroid line facilitates sustainable and scalable generation of functional red cells. Nature Commun 2017;8:1\u20135.","DOI":"10.1038\/ncomms14750"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_088","doi-asserted-by":"crossref","unstructured":"Hawksworth J, Satchwell TJ, Meinders M, et al. Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing. EMBO Mol Med 2018;10:e8454.","DOI":"10.15252\/emmm.201708454"},{"key":"2026082308010209658_j_immunohematology-2025-014_ref_089","doi-asserted-by":"crossref","unstructured":"An HH, Gagne AL, Maguire JA, et al. The use of pluripotent stem cells to generate diagnostic tools for transfusion medicine. Blood 2022;140:1723\u201334.","DOI":"10.1182\/blood.2022015883"}],"container-title":["Immunohematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/immunohematology-2025-014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T08:01:47Z","timestamp":1787472107000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/immunohematology-2025-014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":89,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2025,9,1]]}},"alternative-id":["10.2478\/immunohematology-2025-014"],"URL":"https:\/\/doi.org\/10.2478\/immunohematology-2025-014","relation":{},"ISSN":["1930-3955"],"issn-type":[{"value":"1930-3955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}